摘要:
A three-dimensional structure of human protein kinase C theta (PKCθ) can be used in methods of designing an agent that interacts with PKCθ. The agent can be an inhibitor of PKCθ activity.
摘要:
A three-dimensional structure of protein kinase C theta (PKCθ) can be used in methods of designing an agent that interacts with PKCθ. The agent can be an inhibitor of PKCθ activity.
摘要:
Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed.
摘要:
This disclosure relates to LINGO-1 polypeptides, LINGO-1 polypeptide/ligand complexes, crystals of LINGO-1 polypeptides, crystals of LINGO-1 polypeptide/ligand complexes, and related methods and software systems.
摘要:
Anti-IL-13 antibodies, crystals of anti-IL-13 antibodies, IL-13 polypeptide/anti-IL-13 antibody complexes, crystals of IL-13 polypeptide/anti-IL-13 antibody complexes, IL-13Rα1 polypeptide/IL-13 polypeptide/anti-IL-13 antibody complexes, crystals of IL-13Rα1 polypeptide/IL-13 polypeptide/anti-IL-13 antibody complexes, and related methods and software systems are disclosed.
摘要翻译:抗IL-13抗体,抗IL-13抗体晶体,IL-13多肽/抗IL-13抗体复合物,IL-13多肽/抗IL-13抗体复合物的结晶,IL-13Rα1多肽/ IL -13多肽/抗IL-13抗体复合物,IL-13Rα1多肽/ IL-13多肽/抗IL-13抗体复合物的晶体,以及相关方法和软件系统。
摘要:
This disclosure relates to LINGO-1 polypeptides, LINGO-1 polypeptide/ligand complexes, crystals of LINGO-1 polypeptides, crystals of LINGO-1 polypeptide/ligand complexes, and related methods and software systems.
摘要:
This invention is directed to the crystal structures of MK2, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of MK2 proteins. Such agents may be useful as therapeutic agents.
摘要:
Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed.
摘要:
This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.
摘要:
This invention is directed to the crystal structures of MK2, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of MK2 proteins. Such agents may be useful as therapeutic agents.